https://www.selleckchem.com/pr....oducts/pluripotin-sc
oups to optimise patient outcomes. Management of schizophrenia is complex, requiring consideration of many patient-related and systemic factors. Polypharmacy has a place in certain contexts, however, must be well considered and closely monitored to allow for early identification of opportunities to rationalise (i.e. de-prescribe) therapy, where appropriate. Future research objectives will centre on implementing strategies identified from these focus groups to optimise patient outcomes. This study aimed to identify small extracell
Like
Comment
Share
